RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-1413
Malaria parasiteP. yoelii
Genotype
DisruptedGene model (rodent): PY17X_1123700; Gene model (P.falciparum): PF3D7_0623400; Gene product: MEI2-like RNA-binding protein, putative (PlasMei2)
Transgene
Transgene not Plasmodium: GFP-Luciferase
Promoter: Gene model: PBANKA_1133300; Gene model (P.falciparum): PF3D7_1357100; Gene product: elongation factor 1-alpha (eef1a)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PY03857; Gene product: Pfs230 paralog-related (P230p; 230p)
Phenotype Liver stage;
Last modified: 8 June 2016, 16:44
  *RMgm-1413
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 26883588
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. yoelii
Parent strain/lineP. y. yoelii 17XNL
Name parent line/clone RMgm-689
Other information parent lineRMgm-689 (1971cl1) is a P.y.yoelii 17XNL mutant expressing the fusion protein GFP-Luciferase under the control of the constitutive P. berghei eef1a promoter. The mutant does not contain a drug-selectable marker.
The mutant parasite was generated by
Name PI/ResearcherDankwa DA; Kappe SHI; Vaughan AM
Name Group/DepartmentCenter for Infectious Disease Research
Name InstituteCenter for Infectious Disease Research
CitySeattle
CountryUSA
Name of the mutant parasite
RMgm numberRMgm-1413
Principal nameplasmei2‾
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot different from wild type
Liver stagePlasmei2‾ sporozoites failed to initiate a blood stage infection (after injection of 5x10(4) purified sporozoites). Abnormal development of liver stages. Growth arrest of late liver stages.
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of PlasMei2 and expresses the fusion gene GFP-Luciferase under control of the P. berghei eef1a promoter

Protein (function)
Regulation of mRNA translation relies on RNA binding proteins (RBPs), many of which  form complexes within the cytoplasm in entities known as processing bodies (P-bodies) or P granules. P-bodies are involved in many aspects of mRNA homeostasis including both mRNA decay and translational repression.
Mei2 was initially described in the fission yeast Schizosaccharomyces pombe, and plays a critical role in the switch from mitosis to meiosis (20). Mei2 is a member of the largest family of RBPs – those that contain a RNA recognition motif (RRM), a stretch of 70-90 amino acids that contain two consensus RNA-interacting motifs, RNP1 and RNP2. RRM-containing proteins are subdivided into ten separate families (RRM_1 thru RRM_10) based on shared amino acid identities between members of each family and Mei2 contains a C-terminal RRM_2, thought to be unique to fungi and plants.
Plasmodium contains a single Mei2-like gene (from herein referred to as PlasMei2). In the P. yoelii rodent malaria model, Plasmei2 is only expressed during liver stage development and is localized in distinct cytoplasmic structures reminiscent of P-granules
Mei2-like genes are restricted to eukaryotic genomes and fall into three broad clades, the AML and TEL groups of plants, and a fungal clade. Interestingly, PlasMei2 cannot be exclusively assigned to any one group. Yeast Mei2 contains three RRMs, two N-terminal RRM_1 domains and a C-terminal RRM_2. Only the C-terminal RRM_2 domain is present in PlasMei2.
The Plasmodium RRM_2 shows a high degree of similarity to other Mei2 RRM_2 domains, based on a comparison to representative sequences from alveolates, fungi, and plants. The RRM_2 domain shares amino acid conservation with RRMs of the Sex Lethal and HuD proteins, both of which bind single-stranded AU-rich RNA, suggesting that PlasMei2 may behave similarly.

Phenotype
Normal development/growth of asexual blood stages. Normal sporozoite production. Plasmei2‾ sporozoites failed to initiate a blood stage infection (after injection of 5x10(4) purified sporozoites). Abnormal development of liver stages. Growth arrest of late liver stages. Py plasmei2‾ liver stages increased in size in a similar manner as wildtype parasites during the course of liver stage development. IFA analysis showed no apparent aberrant phenotype of Py plasmei2‾ parasites during the first 28 hours of development. However, by 34 hours, there was evidence for abnormal development. Wildtype liver stages showed numerous nuclear centers but in the majority of Py plasmei2‾ liver stages, there was an increase in the size of a proportion of the nuclear centers, suggesting that abnormal DNA segregation was taking place. This was accompanied by an abnormal expression pattern of the endoplasmic reticulum marker, BiP, which was limited to a perinuclear localization rather than scattered expression throughout the liver stage parasite, typically observed in the wildtype liver stages at this time point. This result suggested that PlasMei2 plays an important role in liver stage endomitosis as early as 34 hours post sporozoite invasion. The phenotype was far more pronounced at the 45-hour time point, and it was clear that normal DNA segregation during endomitosis had ceased, whereas in wildtype parasites, DNA segregation, which precedes exo-erythrocytic merozoite formation, had occurred. The Py plasmei2‾ liver stage mitochondria and apicoplasts also showed signs of unusual development. In the wildtype parasite complex, branched organelle networks were present, but in the Py plasmei2‾ liver stages, the organellar network showed clear signs of abnormal development.
Maturation of liver stage parasites is characterized by cytomere formation; invaginations of the parasite plasma membrane that greatly increase membrane surface area and enable rapid formation of exo-erythrocytic merozoites by individuation throughout the exo-erythrocytic schizont Py plasmei2‾ liver stages at 43 and 48 hours of development did not show cytomere formation and did not contain mature merozoites. MSP1 expression was weak although some parasites showed strong, aggregated expression of MSP1 within the parasite.

Additional information
Evidence is presented that PlasMei2 is only expressed in liver stages. See also RMgm-1414 for a mutant expressing a cmyc-tagged version of PlasMei2. At 20 hours of liver stage development, PlasMei2  expression was not observed, However, by 32 hours of development, PlasMei2 expression was observed throughout the liver stage cytoplasm and exhibited a granular localization pattern reminiscent of P-granule localization. Localization continued to be cytoplasmic and granular as the liver stage parasite matured at both 38 and 45 hours post infection before declining to undetectable levels at 52 hours.

Other mutants
See also RMgm-1414 for a mutant expressing a cmyc-tagged version of PlasMei2.


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PY17X_1123700
Gene Model P. falciparum ortholog PF3D7_0623400
Gene productMEI2-like RNA-binding protein, putative
Gene product: Alternative namePlasMei2
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe plasmei2 gene have been deleted in a P. yoelii GIMO line (RMgm-689; 1971cl1) which is a P.y.yoelii 17XNL mutant expressing the fusion protein GFP-Luciferase under the control of the constitutive P. berghei eef1a promoter. The mutant does not contain a drug-selectable marker.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameGFP-Luciferase
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedureNo
Selection (negative) procedure5-fluorocytosine (5-FC)
Additional remarks genetic modification
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1133300
Gene Model P. falciparum ortholog PF3D7_1357100
Gene productelongation factor 1-alpha
Gene product: Alternative nameeef1a
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PY03857
Gene productPfs230 paralog-related
Gene product: Alternative nameP230p; 230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4